
Emcure Pharmaceuticals Reports 24% Revenue Growth and 29% Rise in PAT in Q2 FY27
Emcure Pharmaceuticals Limited (BSE: 544210, NSE: EMCURE) has reported a strong financial performance for the

Emcure Pharmaceuticals Limited (BSE: 544210, NSE: EMCURE) has reported a strong financial performance for the

Emcure Pharmaceuticals Limited has expanded the use of its co-marketed brand Poviztra® following the approval

Emcure Pharmaceuticals Limited (BSE: 544210 | NSE: EMCURE) has announced the acquisition of the remaining

Emcure Pharmaceuticals has announced a significant price reduction for its weight management therapy Poviztra® (semaglutide

Emcure Pharmaceuticals Ltd (BSE: 544210 | NSE: EMCURE) has announced the nationwide commercial rollout of

Arth by Emcure, a wellness brand that merges scientific innovation with nature, has launched a

Emcure Pharmaceuticals Ltd (BSE: 544210, NSE: EMCURE) announced its consolidated financial results for the quarter

Pune-based Emcure Pharmaceuticals has announced its consolidated financial results for the quarter ending June 30,

Emcure Pharmaceuticals has announced its consolidated financial results for the fourth quarter and full year

Emcutix Biopharmaceuticals Ltd in partnership with Canada-based Mantra Pharma Inc—both subsidiaries of Emcure Pharmaceuticals Ltd—has